BHC:NYE-Bausch Health Companies Inc (USD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | NYE

Last Closing Price

USD 14.88

Change

-0.39 (-2.55)%

Market Cap

USD 5.42B

Volume

4.04M

Average Target Price

USD 22.83 (+53.45%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-29 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ZTS Zoetis Inc

+1.16 (+0.72%)

USD76.65B 46.88 30.55
TKPHF Takeda Pharmaceutical Company ..

N/A

USD60.20B 51.33 0.13
TAK Takeda Pharmaceutical Company ..

-0.85 (-4.48%)

USD59.70B 50.92 0.13
ESALF Eisai Co., Ltd

N/A

USD25.91B 21.85 0.14
SGIOF Shionogi & Co., Ltd

-0.33 (-0.61%)

USD16.14B 15.12 0.08
CTLT Catalent, Inc

+1.08 (+1.28%)

USD13.84B 70.87 23.99
ELAN Elanco Animal Health Incorpora..

-0.30 (-1.11%)

USD12.77B 144.89 54.08
RDY Dr. Reddy's Laboratories Limit..

-0.36 (-0.52%)

USD11.36B 44.33 0.36
TEVA Teva Pharmaceutical Industries..

+0.05 (+0.57%)

USD9.58B 857.00 16.09
PRGO Perrigo Company plc

+0.04 (+0.09%)

USD6.23B 25.71 9.91

ETFs Containing BHC

Symbol Name Weight Mer Price(Change) Market Cap
BSJL Invesco BulletShares 2021.. 0.00 % 0.42 %

+0.05 (+0.22%)

USD0.99B
SHYL Xtrackers Short Duration .. 0.00 % 0.20 %

+0.02 (+0.03%)

USD0.04B
SYBJ:XETRA SPDR Bloomberg Barclays E.. 0.00 % 0.40 %

+0.02 (+0.04%)

USD0.68B
SYBK:F SPDR Bloomberg Barclays 0.. 0.00 % 0.40 %

-0.22 (-0.60%)

USD0.13B
SYBJ:F SPDR Bloomberg Barclays E.. 0.00 % 0.40 %

-0.01 (-0.03%)

USD0.80B
JNKE:PA SPDR Bloomberg Barclays E.. 0.00 % 0.40 %

+0.02 (+0.03%)

USD0.80B
SJNK:LSE SPDR Bloomberg Barclays 0.. 0.00 % 0.40 %

+0.10 (+0.22%)

USD0.11B
JNKS:LSE SPDR Bloomberg Barclays 0.. 0.00 % 0.40 %

+0.03 (+0.09%)

USD0.13B
JNKE:LSE SPDR Bloomberg Barclays E.. 0.00 % 0.40 %

-0.09 (-0.16%)

USD0.80B
HYGV FlexShares High Yield Val.. 0.00 % 0.37 %

N/A

USD0.17B
HYUP Xtrackers High Beta High .. 0.00 % 0.20 %

N/A

USD0.14B
GHYB Goldman Sachs Access High.. 0.00 % 0.34 %

+0.11 (+0.22%)

USD0.06B
CJNK SPDR ICE BofAML Broad Hig.. 0.00 % 0.15 %

N/A

USD0.07B
BSJP Invesco BulletShares 2025.. 0.00 % 0.42 %

N/A

USD0.11B
HYLV IQ S&P High Yield Low Vol.. 0.00 % 0.40 %

+0.03 (+0.10%)

USD0.10B
HYLB Xtrackers USD High Yield .. 0.00 % 0.15 %

+0.06 (+0.13%)

USD4.54B
SJNK SPDR Bloomberg Barclays S.. 0.00 % 0.40 %

+0.01 (+0.04%)

USD2.99B
SJB ProShares Short High Yiel.. 0.00 % 0.95 %

-0.04 (-0.20%)

USD0.10B
RFUN RiverFront Dynamic Uncons.. 0.00 % 0.52 %

+0.01 (+0.02%)

USD0.01B
JNK SPDR Bloomberg Barclays H.. 0.00 % 0.40 %

+0.08 (+0.08%)

USD10.52B
HYLS First Trust Tactical High.. 0.00 % 1.23 %

+0.09 (+0.19%)

USD1.97B
HYG iShares iBoxx $ High Yiel.. 0.00 % 0.49 %

+0.07 (+0.08%)

USD26.78B
SYBK:XETRA SPDR Bloomberg Barclays 0.. 0.00 % 0.40 %

-0.24 (-0.63%)

USD0.13B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -50.27% 15% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -50.27% 15% F 9% F
Trailing 12 Months  
Capital Gain -24.35% 37% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.35% 37% F 23% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -3.63% N/A N/A 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.63% N/A N/A 19% F
Risk Return Profile  
Volatility (Standard Deviation) 17.76% N/A N/A 45% F
Risk Adjusted Return -20.43% N/A N/A 21% F
Market Capitalization 5.42B 59% F 77% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 11.40 7% F 6% F
Price / Cash Flow Ratio 3.61 38% F 60% D-
EV/EBITDA 20.61 22% F 22% F
Management Effectiveness  
Return on Equity -126.28% 4% F 3% F
Return on Invested Capital -0.55% 37% F 19% F
Return on Assets 2.24% 52% F 52% F
Debt to Equity Ratio 2,319.94% 4% F 1% F
Technical Ratios  
Short Ratio 4.04 65% D 28% F
Short Percent 5.29% 60% D- 48% F
Beta 1.14 42% F 44% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector